Niall C. Tebbutt

145 Studley Road
Heidelberg, VIC 3084, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 165 publications

An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal.

An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal.

Journal: Expert review of anticancer therapy

Published: July 22, 2026

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Journal: The New England journal of medicine

Published: May 27, 2026

Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective.

Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective.

Journal: Clinical colorectal cancer

Published: January 22, 2026

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.

LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.

Journal: Future oncology (London, England)

Published: November 24, 2025

MR-Guided Radiotherapy in Oesophageal Cancer: From Principles to Practice-A Narrative Review.

MR-Guided Radiotherapy in Oesophageal Cancer: From Principles to Practice-A Narrative Review.

Journal: Current oncology (Toronto, Ont.)

Published: October 26, 2025

Triple M Syndrome Associated With Concurrent Durvalumab and Olaparib Therapy in Metastatic Cholangiocarcinoma: A Case Report.

Triple M Syndrome Associated With Concurrent Durvalumab and Olaparib Therapy in Metastatic Cholangiocarcinoma: A Case Report.

Journal: Case reports in oncological medicine

Published: October 06, 2025

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.

Journal: Nature medicine

Published: September 05, 2025

Differentiation grade is highly concordant between matched primary and metastatic colorectal cancer.

Differentiation grade is highly concordant between matched primary and metastatic colorectal cancer.

Journal: Clinical & experimental metastasis

Published: July 05, 2025

The current landscape of neoadjuvant therapy for resectable colon cancer.

The current landscape of neoadjuvant therapy for resectable colon cancer.

Journal: Expert review of anticancer therapy

Published: June 06, 2025

Fosl1 is a transcriptional effector of BRAF V600E-driven intestinal tumorigenesis.

Fosl1 is a transcriptional effector of BRAF V600E-driven intestinal tumorigenesis.

Journal: iScience

Published: May 19, 2025

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 05, 2025

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Journal: Cell reports. Medicine

Published: December 28, 2024

Showing 1-12 of 165

Last Updated: 09/26/2026